Skip to main content

Nexstim Plc has granted stock options to its CEO and other members of the management team

Written by Customer Service on . Posted in Public Companies.

Company announcement, Helsinki, 16 June 2020, at 7.30 pm EET
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) announces that pursuant to the stock option program 2020 announced on 10 July 2020, the Board of Directors has resolved to grant in total 8 386 667  stock options to its CEO which entitle to subscribe for a maximum of 8 386 667  new shares in Nexstim in accordance with stock option terms approved on 10 June 2020. Accordingly, the Board of Directors has resolved to grant in total 14 280 000  stock options to other members of its management group which entitle to subscribe for a maximum of 14 280 000  new shares in Nexstim in accordance with stock option terms approved on 10 June 2020.2 590 000  of such stock options granted to the CEO are series 2020A options, 2 836 667 are series 2020B options and 2 960 000 series 2020C options, and 4 410 000 of such stock options granted to the other members of the management group are series 2020A options, 4 830 000 are series 2020B options and 5 040 000 series 2020C options.NEXSTIM PLCLeena Niemistö, Chair of the Board of DirectorsFurther information is available on the website www.nexstim.com or by contacting:Leena Niemistö, Chair of the Board of Directors
 +358 9 2727 170
leena.niemisto@nexstim.comErik Penser Bank AB (Certified Adviser)                                                                                                                                  
+46 8 463 83 00
certifiedadviser@penser.seAbout Nexstim PlcNexstim is a Finnish medical technology company operating in international markets. Our mission is to enable the individual and efficient diagnosis and treatment of challenging brain diseases and disorders. Nexstim has developed a pioneering non-invasive brain stimulation technology entitled SmartFocus®. SmartFocus® is based on transcranial magnetic stimulation (TMS) combined with a 3D navigation system. The unique technology allows the required area of brain to be stimulated accurately and individually.The SmartFocus® TMS technology is used in NBT® (Navigated Brain Therapy) equipment developed by Nexstim. Marketing and distribution of the equipment for the treatment of serious depression in the USA has been authorised by FDA. NBT® equipment has been CE approved in Europe for the treatment of serious depression and chronic neuropathic pain.Furthermore, Nexstim is marketing the Navigated Brain Stimulation (NBS) equipment, developed by it and based on   SmartFocus® TMS technology. Nexstim’s NBS system is the only FDA cleared and CE marked navigating TMS equipment for the pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden trading facilities.For more information, please visit www.nexstim.comAttachmentNexstim Company Announcement_16062020_granting of options_ENG_FINAL

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.